Identifying the Optimum Strategy for Identifying Adults and Children With Celiac Disease : A Cost-Effectiveness and Value of Information Analysis
Copyright © 2024. Published by Elsevier Inc..
OBJECTIVES: Celiac disease (CD) is thought to affect around 1% of people in the United Kingdom, but only approximately 30% are diagnosed. The aim of this work was to assess the cost-effectiveness of strategies for identifying adults and children with CD in terms of who to test and which tests to use.
METHODS: A decision tree and Markov model were used to describe testing strategies and model long-term consequences of CD. The analysis compared a selection of pre-test probabilities of CD above which patients should be screened, as well as the use of different serological tests, with or without genetic testing. Value of information analysis was used to prioritize parameters for future research.
RESULTS: Using serological testing alone in adults, immunoglobulin A (IgA) tissue transglutaminase (tTG) at a 1% pre-test probability (equivalent to population screening) was most cost-effective. If combining serological testing with genetic testing, human leukocyte antigen combined with IgA tTG at a 5% pre-test probability was most cost-effective. In children, the most cost-effective strategy was a 10% pre-test probability with human leukocyte antigen plus IgA tTG. Value of information analysis highlighted the probability of late diagnosis of CD and the accuracy of serological tests as important parameters. The analysis also suggested prioritizing research in adult women over adult men or children.
CONCLUSIONS: For adults, these cost-effectiveness results suggest UK National Screening Committee Criteria for population-based screening for CD should be explored. Substantial uncertainty in the results indicate a high value in conducting further research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 27(2024), 3 vom: 01. März, Seite 301-312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keeney, Edna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Celiac disease |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jval.2023.12.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366452363 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366452363 | ||
| 003 | DE-627 | ||
| 005 | 20240425232626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jval.2023.12.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM366452363 | ||
| 035 | |a (NLM)38154593 | ||
| 035 | |a (PII)S1098-3015(23)06243-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keeney, Edna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identifying the Optimum Strategy for Identifying Adults and Children With Celiac Disease |b A Cost-Effectiveness and Value of Information Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a OBJECTIVES: Celiac disease (CD) is thought to affect around 1% of people in the United Kingdom, but only approximately 30% are diagnosed. The aim of this work was to assess the cost-effectiveness of strategies for identifying adults and children with CD in terms of who to test and which tests to use | ||
| 520 | |a METHODS: A decision tree and Markov model were used to describe testing strategies and model long-term consequences of CD. The analysis compared a selection of pre-test probabilities of CD above which patients should be screened, as well as the use of different serological tests, with or without genetic testing. Value of information analysis was used to prioritize parameters for future research | ||
| 520 | |a RESULTS: Using serological testing alone in adults, immunoglobulin A (IgA) tissue transglutaminase (tTG) at a 1% pre-test probability (equivalent to population screening) was most cost-effective. If combining serological testing with genetic testing, human leukocyte antigen combined with IgA tTG at a 5% pre-test probability was most cost-effective. In children, the most cost-effective strategy was a 10% pre-test probability with human leukocyte antigen plus IgA tTG. Value of information analysis highlighted the probability of late diagnosis of CD and the accuracy of serological tests as important parameters. The analysis also suggested prioritizing research in adult women over adult men or children | ||
| 520 | |a CONCLUSIONS: For adults, these cost-effectiveness results suggest UK National Screening Committee Criteria for population-based screening for CD should be explored. Substantial uncertainty in the results indicate a high value in conducting further research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a celiac disease | |
| 650 | 4 | |a cost-effectiveness analysis | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a value of information analysis | |
| 650 | 7 | |a Transglutaminases |2 NLM | |
| 650 | 7 | |a EC 2.3.2.13 |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a HLA Antigens |2 NLM | |
| 700 | 1 | |a Elwenspoek, Martha M C |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Joni |e verfasserin |4 aut | |
| 700 | 1 | |a Roadevin, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Hayley E |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Sheppard, Athena L |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Stubbs, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Everitt, Hazel |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Jessica C |e verfasserin |4 aut | |
| 700 | 1 | |a Hay, Alastair D |e verfasserin |4 aut | |
| 700 | 1 | |a Gillett, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Robins, Gerry |e verfasserin |4 aut | |
| 700 | 1 | |a Mallett, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Whiting, Penny F |e verfasserin |4 aut | |
| 700 | 1 | |a Thom, Howard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research |d 1998 |g 27(2024), 3 vom: 01. März, Seite 301-312 |w (DE-627)NLM115934545 |x 1524-4733 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:301-312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jval.2023.12.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2024 |e 3 |b 01 |c 03 |h 301-312 | ||